AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Akari Therapeutics PLC (AKTX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C- (2.1) | C (2.3) | C+ (2.7) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-08-04 | C- (2.1) | C (2.3) | C+ (2.7) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-08-03 | C- (2.1) | C (2.4) | C- (2.0) | C (2.4) | C- (2.0) | C (2.2) |
| 2026-08-02 | C- (2.1) | C (2.4) | C- (2.0) | C (2.4) | C- (1.9) | C (2.2) |